<DOC>
	<DOCNO>NCT01651780</DOCNO>
	<brief_summary>The objective study assess safety efficacy use bivalirudin instead unfractionated heparin ( UFH ) transcatheter aortic valve replacement ( TAVR ) . The primary hypothesis BRAVO 3 bivalirudin would reduce major bleeding compare heparin TAVR procedure . Results participant enrol randomize trial ( BRAVO 3 ) present .</brief_summary>
	<brief_title>Open-label , Randomized Trial Participants Undergoing TAVR Determine Safety &amp; Efficacy Bivalirudin v UFH</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>Males female , ≥18 year age High risk ( Euroscore ≥18 , consider inoperable ) surgical aortic valve replacement Undergoing TAVR via transfemoral arterial access Provide write informed consent initiation study related procedure Any know contra‐indication use bivalirudin ( except presence severe renal impairment [ glomerular filtration rate ( GFR ) &lt; 30 milliliter ( mL ) /minute ] since participant include trial UFH Refusal receive blood transfusion Mechanical valve ( location ) mitral bioprosthetic valve Extensive calcification common femoral artery , minimal luminal diameter &lt; 6.5 millimeter ( mm ) Use elective surgical cutdown transfemoral access Concurrent performance percutaneous coronary intervention TAVR International normalize ratio ( INR ) ≥2 day TAVR procedure know history bleed diathesis History hemorrhagic stroke , intracranial hemorrhage , intracerebral mass aneurysm , arteriovenous malformation Severe leave ventricular dysfunction ( left ventricular ejection fraction &lt; 15 % ) Severe aortic regurgitation mitral regurgitation ( 4+ ) Hemodynamic instability ( example , require inotropic intraaortic balloon pump support ) within 2 hour procedure Dialysis dependent Administration thrombolytic , glycoprotein IIb/IIIa inhibitor , warfarin 3 day prior procedure Acute myocardial infarction , major surgery , therapeutic cardiac procedure ( balloon aortic valvuloplasty ) within 30 day Percutaneous coronary intervention within 30 day Upper gastrointestinal genitourinary bleed within 30 day Stroke transient ischemic attack within 30 day Any surgery biopsy within 2 week Administration : UFH within 30 minute procedure Enoxaparin within 8 hour procedure Fondaparinux lowmolecularweight heparin ( LMWHs ) within 24 hour procedure Dabigatran , rivaroxaban , oral antiXa antithrombin agent within 48 hour procedure Thrombolytics , glycoprotein IIb/IIIa inhibitor , warfarin within 72 hour procedure Absolute contraindication allergy premedicated iodinated contrast Contraindications allergy aspirin clopidogrel Known suspect pregnant woman nurse mother . Women child‐bearing potential ask pregnant test pregnancy Previous enrollment study Treatment investigational drug device within 30 day precede enrollment plan use investigational drug device primary endpoint study reach</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Transcatheter aortic valve replacement</keyword>
	<keyword>Aortic valve replacement</keyword>
	<keyword>Severe aortic stenosis</keyword>
</DOC>